International › Norway · Last reviewed 2026-05-16

Norway — Ukom 2023

Summary

In March 2023 the Norwegian Healthcare Investigation Board (Ukom) published a report recommending that puberty blockers and hormonal and surgical gender-affirming treatment of children and young people be defined as experimental treatment ("utprøvende behandling"). Ukom also recommended revising the national guideline on the basis of a systematic knowledge summary, and that a national quality registry be considered (source).

1. Ukom report March 2023

The Norwegian Statens undersøkelseskommisjon for helse- og omsorgstjenesten (Ukom) is an independent government body for investigating patient safety. In March 2023 Ukom published the report "Pasientsikkerhet for barn og unge med kjønnsinkongruens", with findings including:

  • Ukom considers the knowledge base for hormonal and surgical gender-affirming treatment inadequate, the long-term effects little known and the stability of gender incongruence in teenagers unknown, and recommends defining the treatment as experimental ("utprøvende behandling").
  • Norway has no systematic knowledge summary for this field; applying the principles for experimental treatment would ensure information, thorough follow-up and more knowledge.
  • The national guideline is weakly normative and sets no specific requirements for assessment or for the medical indication.

2. Recommendations

Ukom recommended that the Ministry of Health and Care Services instruct the Norwegian Directorate of Health (Helsedirektoratet) to revise the national guideline on gender incongruence on the basis of a systematic knowledge summary, and that the ministry consider a national medical quality registry and systematic data collection to support structural follow-up research (source).1

See also

Footnotes

  1. Ukom. Pasientsikkerhet for barn og unge med kjønnsinkongruens. 9 March 2023.